Senger Carolin, Kluge Anne, Kord Melina, Zimmermann Zoe, Conti Alfredo, Kufeld Markus, Kreimeier Anita, Loebel Franziska, Stromberger Carmen, Budach Volker, Vajkoczy Peter, Acker Gueliz
Department of Radiation Oncology, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Augustenburger Platz 1, 13353 Berlin, Germany.
Charité Cyberknife Center, Augustenburger Platz 1, 13353 Berlin, Germany.
Cancers (Basel). 2021 Apr 30;13(9):2165. doi: 10.3390/cancers13092165.
The role of robotic radiosurgery (RRS) in the treatment of optic nerve sheath meningiomas (ONSM) remains controversial and it is only performed in specialized institutions due to tight dose constraints. We evaluated the effectiveness and safety of RRS in the management of ONSM. Twenty-five patients with 27 ONSM lesions who underwent RRS using the Cyberknife (CK) system were retrospectively analyzed (median age, 47.9 years; 84.0% women). Multisession RRS was used with 4-5 fractions with a cumulative dose of 20.0-25.0 Gy in 84.0% of patients and a single fraction at a dose of 14.0-15.0 Gy in 16% of patients. Prior to RRS, seven (28%) patients experienced blindness on the lesion side. In those patients with preserved vision prior to radiosurgery, the visual acuity remained the same in 90.0% and improved in 10.0% of the patients. Overall local tumor control was 96.0% (mean follow-up period; 37.4 ± 27.2 months). Neither patient age, previous surgery, or the period from the initial diagnosis to RRS showed a dependency on visual acuity before or after radiosurgery. RRS is a safe and effective treatment for the management of ONSM. Hypofractionation of radiosurgery in patients with preserved vision before CK treatment results in stable or improved vision.
机器人放射外科手术(RRS)在视神经鞘膜瘤(ONSM)治疗中的作用仍存在争议,由于剂量限制严格,仅在专业机构开展。我们评估了RRS治疗ONSM的有效性和安全性。对25例患有27个ONSM病灶且使用射波刀(CK)系统接受RRS治疗的患者进行回顾性分析(中位年龄47.9岁;84.0%为女性)。84.0%的患者采用多疗程RRS,分4 - 5次分割,累积剂量为20.0 - 25.0 Gy,16%的患者采用单次分割,剂量为14.0 - 15.0 Gy。RRS治疗前,7例(28%)患者患侧失明。在放射外科手术前视力保留的患者中,90.0%的患者视力保持不变,10.0%的患者视力改善。总体局部肿瘤控制率为96.0%(平均随访期;37.4±27.2个月)。患者年龄、既往手术情况或从初始诊断到RRS的时间与放射外科手术前后的视力均无相关性。RRS是治疗ONSM的一种安全有效的方法。CK治疗前视力保留的患者采用大分割放射外科手术可使视力稳定或改善。